Workup for Axillary Mass in 35-Year-Old Female
Begin with axillary ultrasound as the primary initial imaging modality, complemented by diagnostic mammography and/or digital breast tomosynthesis to evaluate for an underlying breast primary. 1
Initial Imaging Approach
The appropriate workup follows a structured algorithm based on the 2022 ACR Appropriateness Criteria for imaging of the axilla 1:
Primary Imaging: Axillary Ultrasound
Axillary ultrasound is the most appropriate first-line imaging test for evaluating a palpable axillary mass 1. This modality:
- Distinguishes solid from cystic lesions
- Characterizes lymph node morphology versus other masses
- Identifies accessory breast tissue and associated lesions 2, 3
- Enables immediate US-guided biopsy if suspicious features are present
- Has no radiation exposure
Complementary Breast Imaging
Diagnostic mammography and/or digital breast tomosynthesis should be performed concurrently to evaluate for an underlying breast primary, as NCCN guidelines recommend evaluating the breast when axillary lymphadenopathy is present 1. This is critical because:
- The most common malignant cause of axillary adenopathy is ipsilateral breast cancer 1
- However, only 7% of axillary masses in women without breast cancer history prove malignant 1
- DBT shows particular benefit in women ages 40-49 years for detecting occult breast primaries 1
Differential Diagnosis Considerations
At age 35, the differential diagnosis is broad 1:
Benign etiologies (most common):
- Reactive lymphadenopathy (infectious/inflammatory)
- Ectopic/accessory breast tissue with fibrocystic changes or fibroadenoma 2, 4, 3
- Lipomas
- Nerve sheath tumors
Malignant etiologies (less common but critical):
- Metastatic breast cancer (most common if malignant)
- Lymphoma
- Other metastatic disease
Biopsy Indications
Perform US-guided core needle biopsy if:
- Suspicious sonographic features are identified (irregular margins, loss of fatty hilum, increased vascularity, cortical thickening >3mm)
- The mass cannot be definitively characterized as benign
- Clinical concern persists despite benign-appearing imaging 4, 5
Core needle biopsy is preferred over fine needle aspiration for definitive tissue diagnosis 4.
What NOT to Do Initially
Do not start with:
- FDG-PET/CT: Not beneficial as initial imaging because it has low yield for detecting occult primary malignancy without first confirming malignant etiology 1. Less than 1% of breast cancers present as isolated axillary adenopathy 1
- CT chest/abdomen/pelvis: Not indicated unless systemic disease or chest wall involvement is suspected 1
- Breast MRI: Reserved for problem-solving when US shows adenopathy of unknown primary and mammography is negative 1
- Mammography alone: Insufficient as sole imaging test, though enlarged nodes may be visible on mediolateral oblique views 1
Clinical Pitfalls to Avoid
Don't assume benign based on age alone: While malignancy risk increases with age (mean age 55 years for malignant vs. 43 years for benign pathology 5), malignancies including breast cancer can occur at age 35 4, 6
Don't miss ectopic breast tissue: Accessory breast tissue is present in up to 6% of women and can develop fibroadenomas, fibrocystic changes, or even carcinoma 2, 4, 7. This can be mistaken for lymphadenopathy or other pathology 7
Don't overlook contralateral breast: In cases of occult breast cancer presenting as axillary mass, 5 of 9 patients in one series had contralateral breast primaries 5
Follow-up Based on Initial Findings
If imaging shows benign features and biopsy confirms benign pathology:
- Clinical follow-up or observation may be appropriate
- Complete excision can be considered for symptomatic lesions or patient preference 4
If malignancy is confirmed:
- Proceed with appropriate staging (may then include MRI, PET/CT)
- Multidisciplinary tumor board discussion
- Sentinel lymph node biopsy has replaced axillary lymph node dissection as standard for staging in most breast cancer scenarios 1